Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The REDUC trial's objective is to address one of the core issues with the treatment of HIV,
which is that some HIV infected cells hide in so-called latent reservoirs. The reservoirs are
unaffected by conventional HIV medication and invisible to the immune system. HDACi have the
potential to activate these latently infected cells. This will make the HIV infected cells
visible to the immune system; the immune response generate by Vacc-4x will be able to attack
and eliminate the infected cells.